PK of Cenicriviroc in Severe Hepatic Impairment

Phase 1, open-label trial of cenicriviroc in Nonalcoholic steatohepatitis (NASH) and Liver Fibrosis (LF) (2 arms), sponsored by Allergan. Primary endpoints: Area under the plasma concentration versus time curve from time 0 to time t at 6 days, Area under the plasma concentration versus time curve from time 0 to infinity at 6 days and 1 more. Started Jun 2017; status: completed.